



MMV-supported projects



Target product profiles (TPPs)

- 3-day cure, artemisinin-based combination therapies (TPP1)
- Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP1)
- Intermittent preventive treatment (TPP1)
- Severe malaria treatment/pre-referral intervention (TPP1)
- Products targeting prevention of relapse for *P. vivax* (TPP1)
- Prophylaxis (TPP2)

Brand names: 1. Coartem® *Dispersible*; 2. Artesun®; 3. Larinate® 60mg; 4. Eurartesim®; 5. Pyramax® tablets or granules; 6. ASAQ Winthrop®; 7. SPAQ-CO™; 8. Supyra®; 9. 100 mg Artesunate Rectocaps; 10. Artecip™; 11. *Krintafel/Kozenis* (Trademarks owned or licensed by GSK)

To develop the individual compounds for combination into the TPPs, MMV has defined five target candidate profiles (TCPs):

- Asexual blood stages (TCP 1)
- Relapse prevention (TCP 3)
- Causal prophylaxis (TCP 4)
- Transmission reduction (TCP 5, 6)

- Included in MMV portfolio after product approval and/or development
- Global Fund Expert Review Panel reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing
- Paediatric formulation
- WHO prequalified OR approved/positive opinion by regulatory bodies who are ICH* members/observers
- Via a bioequivalence study
- (-) Past partners are in brackets

* International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use